Analyses on safety and efficacy of non-standard dose of r-tPA in intravenous thrombolysis-treated AIS patients

BACKGROUND: Intravenous 0.9 mg/kg recombinant tissue plasminogen activator (r-tPA) is one of the most effective treatments in acute ischemic stroke patients. Practically, the dose of r-tPA is still a topic that is constantly being discussed. METHODS: For this observational study, data were obtained...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Jiawen, Wu, Ruxing, Xiang, Jingyan, Deng, Jiangshan, Zhang, Xiaojie, Lu, Kaili, Cao, Fengya, Zhao, Fei, Zhao, Yuwu, Wang, Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705228/
https://www.ncbi.nlm.nih.gov/pubmed/36457872
http://dx.doi.org/10.3389/fneur.2022.1007167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705228/
https://www.ncbi.nlm.nih.gov/pubmed/36457872
http://dx.doi.org/10.3389/fneur.2022.1007167

Ejemplares similares